A new imaging tracer could predict immunotherapy success in lung cancer
NCT ID NCT05701176
First seen Aug 18, 2026 · Last updated Aug 18, 2026
Summary
This study tests whether a special PET scan tracer, [18F]F-AraG, can visualize activated T-cells in tumors and healthy tissue of patients with advanced non-small cell lung cancer. The goal is to see if changes in tracer uptake during anti-PD-1 immunotherapy can predict how well the treatment works. Participants will undergo PET scans before starting therapy and again after 2 and 6 weeks of treatment, with results compared to tumor response at 6 and 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A PET imaging tracer called [18F]F-AraG, used to visualize activated T-cells in the body.
- What this could lead to
- If successful, this imaging method could help doctors predict early whether immunotherapy is working in lung cancer, guiding treatment decisions.
- What could go wrong
- This is a small early-stage study, and the tracer's ability to predict response is unproven. It may not reliably reflect T-cell activity or correlate with treatment outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED STAGE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Amsterdam UMC, location VU University Medical Center
RECRUITINGAmsterdam, 1081 HV, Netherlands